Serum carboxy-terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function

Circulation Journal

Volumn 71, Issue 6, 2007, Pages 929-935

  Kitahara, Tatsuro ^a   Takeishi, Yasuchika ^a   Arimoto, Takanori ^a   Niizeki, Takeshi ^a   Koyama, Yo ^a   Sasaki, Toshiki ^a   Suzuki, Satoshi ^a   Nozaki, Naoki ^a   Hirono, Osamu ^a   Nitobe, Joji ^a   Watanabe, Tetsu ^a   Kubota, Isao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Carboxy terminal telopeptide of type I collagen (ICTP); Diastolic HF; Prognosis

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE;

ADULT; AGED; ARTICLE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COLLAGEN TYPE I; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

EID: 34249715854     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.929     Document Type: Article

References (31)

1. Franklin KM, Aurigemma GP. Prognosis in diastolic heart failure. Prog Cardiovasc Dis 2005; 47: 333-339.
2. Brilla CG, Maisch B, Zhou G, Weber KT. Hormonal regulation of cardiac fibroblast function. Eur Heart J 1995; 16(Suppl): C45-C50.
3. Arimoto T, Takeishi Y, Shiga R, Fukui A, Tachibana H, Nozaki N, et al. Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure. J Card Fail 2005; 11: 56-60.
4. Arimoto T, Takeishi Y, Niizeki T, Takabatake N, Okuyama H, Fukui A, et al. Cystatin C is a novel predictor of cardiac events in patients with chronic heart failure. J Card Fail 2005; 11: 595-601.
5. Niizeki T, Takeishi Y, Arimoto T, Takahashi T, Okuyama H, Takabatake N, et al. A combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure. Circ J 2005; 69: 922-927.
6. Niizeki T, Takeishi Y, Arimoto T, Takabatake N, Nozaki N, Hirono O, et al. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chrnonic heart failure patients. J Card Fail 2007; 13: 120-127.
7. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-640.
8. Hadano Y, Murata K, Liu J, Oyama R, Harada N, Okuda S, et al. Can transthoracic Doppler echocardiography predict the discrepancy between left ventricular end-diastolic pressure and mean pulmonary capillary wedge pressure in patients with heart failure? Circ J 2005; 69: 432-438.
9. Janicki JS, Collagen degradation in the heart. In: Eghbali-Webb M, Editor. Molecular biology of collagen matrix in the heart. Austin, TX: RG Landes; 1995; 61-76.
10. Risteli L, Risteli J. Noninvasive methods for detection of organ fibrosis. In: Rojkind M, Editor. Connective tissue in health and disease. Boca Raton, FL: CRC Press; 1990; 61-98.
11. Gaasch WH, Zile MR. Diastolic dysfunction and diastolic heart failure. Annu Rev Med 2004; 55: 373-394.
12. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002; 55: 76-82.
13. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 2002; 4: 439-444.
14. Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Miranda M, et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 2003; 108: 1455-1460.
15. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: A marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40: 136-141.
16. Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43: 2028-2035.
17. Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38: 1222-1226.
18. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535-540.
19. Diez J, Panizo A, Gil M, Monreal I, Hemandez M, Pardo Mindan J. Serum markers of collagen type I metabolism in spontaneously hypertensive rat: Relation to myocardial fibrosis. Circulation 1996; 93: 1026-1032.
20. American College of Cardiology/American Heart Association. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Available at: http://www.acc.org/clinical/guidelines/failure//index.pdf
21. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
22. Luchner A, Muders F, Dietl O, Friedrich E, Blumberg F, Protter AA, et al. Differential expression of cardiac ANP and BNP in a rabbit model of progressive left ventricular dysfunction. Cardiovasc Res 2001; 51: 601-607.
23. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
24. Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988-994.
25. Yamamoto K, Burnett JC Jr, Bermudez EA, Joukasaki M, Bailey KR, Redfield MM. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail 2000; 6: 194-200.
26. Von Lukowicz T, Fischer M, Stritzke J, Riegger GA, Schunkert H, Luchner A. BNP as a marker of diastolic function in the general population: Importance of left ventricular hypertrophy. Eur J Heart Fail 2005; 7: 525-531.
27. Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol 2003; 92: 1434-1438.
28. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Jacobsen SJ, Mahoney DW, Bailey KR, et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction. A community-based study. Circulation 2004; 109: 3176-3181.
29. Janicki JS. Collagen degradation in the heart. In: Eghbali-Webb M, editor. Molecular biology of collagen matrix in the heart. Austin: Landes; 1995; 61-76.
30. Oie E, Yndestad A, Robin SP, Bornerheim R, Asberg A, Attramadal H. Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats. Basic Res Cardiol 2002; 97: 239-247.
31. Mori T, Hayashi T, Sohmiya K, Okuda N, Shimomura H, Ohkita M, et al. Mechanisms of combined treatment with celiprolol and candesartan for ventricular remodeling in experimental heart failure. Circ J 2005; 69: 596-602.